UK markets closed

MagForce AG (MGFRF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.25000.0000 (0.00%)
At close: 10:24AM EDT

MagForce AG

Max-Planck-Strasse 3
Berlin 12489
49 30 308 380 0

IndustryMedical Devices
Full-time employees34

Key executives

NameTitlePayExercisedYear born
Dr. Benjamin J. LippsChairman of the Management Board & CEON/AN/A1940
Mr. Christian Von VolkmannCFO & Member of Management BoardN/AN/A1971
Dr. Andreas JordanExec. VP, Chief Scientific Officer & MD of EuropeN/AN/A1959
Ms. Barbara Von FrankenbergVP of Communications & Investor RelationsN/AN/AN/A
Ms. Solveig SalomonVP of Marketing & Sales and European Commercial DirectorN/AN/AN/A
Dr. Hans Joachim Hutt M.D., Ph.D.Medical ConsultantN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


MagForce AG operates in the field of nanotechnology-based cancer therapy in Germany and Poland. It offers NanoTherm, a therapy for the treatment of solid tumors; NanoPlan, a simulation software that helps the treating physicians to define the NanoTherm therapy schedule according to the distribution of the NanoTherm depots in the tumor; and NanoActivator, a magnetic field applicator. MagForce AG was founded in 1997 and is headquartered in Berlin, Germany.

Corporate governance

MagForce AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.